Zobraziť v EDS

Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study

Uložené v:
Podrobná bibliografia
Názov: Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study
Autori: Camporesi, Sara, Xin, Lijing, Golay, Philippe, Eap, Chin Bin, Cleusix, Martine, Cuenod, Michel, Fournier, Margot, Hashimoto, Kenji, Jenni, Raoul, Ramain, Julie, Restellini, Romeo, Solida, Alessandra, Conus, Philippe, Do, Kim Q, Khadimallah, Ines
Zdroj: Mol Psychiatry
Molecular psychiatry, vol. 29, no. 11, pp. 3669-3679
Camporesi, Sara; Xin, Lijing; Golay, Philippe; Eap, Chin Bin; Cleusix, Martine; Cuenod, Michel; Fournier, Margot; Hashimoto, Kenji; Jenni, Raoul; Ramain, Julie; Restellini, Romeo; Solida, Alessandra; Conus, Philippe; Do, Kim Q; Khadimallah, Ines (2024). Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study. (In Press). Molecular psychiatry Springer Nature 10.1038/s41380-024-02631-4 <http://dx.doi.org/10.1038/s41380-024-02631-4>
Camporesi, Sara; Xin, Lijing; Golay, Philippe; Eap, Chin Bin; Cleusix, Martine; Cuenod, Michel; Fournier, Margot; Hashimoto, Kenji; Jenni, Raoul; Ramain, Julie; Restellini, Romeo; Solida, Alessandra; Conus, Philippe; Do, Kim Q; Khadimallah, Ines (2024). Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study. Molecular psychiatry, 29(11), pp. 3669-3679. Springer Nature 10.1038/s41380-024-02631-4 <http://dx.doi.org/10.1038/s41380-024-02631-4>
Informácie o vydavateľovi: Springer Science and Business Media LLC, 2024.
Rok vydania: 2024
Predmety: Male, Adult, Adolescent, Psychotic Disorders / metabolism, Glutamic Acid, 610 Medicine & health, Schizophrenia, Treatment-Resistant / metabolism, Glutamic Acid / metabolism, Neuropsychological Tests, Humans, Female, Longitudinal Studies, Psychotic Disorders/drug therapy, Psychotic Disorders/metabolism, Receptors, N-Methyl-D-Aspartate/metabolism, Young Adult, Follow-Up Studies, Cognitive Dysfunction/drug therapy, Cognitive Dysfunction/metabolism, Antipsychotic Agents/therapeutic use, Antipsychotic Agents/pharmacology, Case-Control Studies, Cognition/physiology, Cognition/drug effects, Schizophrenia, Treatment-Resistant/drug therapy, Schizophrenia, Treatment-Resistant/metabolism, Glutamic Acid/metabolism, Schizophrenia/drug therapy, Schizophrenia/metabolism, Brain/metabolism, Receptors, N-Methyl-D-Aspartate, Receptors, N-Methyl-D-Aspartate / metabolism, Article, Cognition, Psychotic Disorders / drug therapy, Cognitive Dysfunction, Cognition / physiology, Cognitive Dysfunction / drug therapy, Schizophrenia / metabolism, Antipsychotic Agents / pharmacology, Schizophrenia, Treatment-Resistant / drug therapy, Schizophrenia / drug therapy, Brain, Cognitive Dysfunction / metabolism, Psychotic Disorders, Cognition / drug effects, 616.89, Schizophrenia, Brain / metabolism, Antipsychotic Agents / therapeutic use, Schizophrenia, Treatment-Resistant, Antipsychotic Agents
Popis: This study aims to determine whether 1) individuals with treatment-resistant schizophrenia display early cognitive impairment compared to treatment-responders and healthy controls and 2) N-methyl-D-aspartate-receptor hypofunction is an underlying mechanism of cognitive deficits in treatment-resistance. In this case‒control 3-year-follow-up longitudinal study, n = 697 patients with first-episode psychosis, aged 18 to 35, were screened for Treatment Response and Resistance in Psychosis criteria through an algorithm that assigns patients to responder, limited-response or treatment-resistant category (respectively resistant to 0, 1 or 2 antipsychotics). Assessments at baseline: MATRICS Consensus Cognitive Battery; N-methyl-D-aspartate-receptor co-agonists biomarkers in brain by MRS (prefrontal glutamate levels) and plasma (D-serine and glutamate pathways key markers). Patients were compared to age- and sex-matched healthy controls (n = 114). Results: patient mean age 23, 27% female. Treatment-resistant (n = 51) showed lower scores than responders (n = 183) in processing speed, attention/vigilance, working memory, verbal learning and visual learning. Limited responders (n = 59) displayed an intermediary phenotype. Treatment-resistant and limited responders were merged in one group for the subsequent D-serine and glutamate pathway analyses. This group showed D-serine pathway dysregulation, with lower levels of the enzymes serine racemase and serine-hydroxymethyltransferase 1, and higher levels of the glutamate-cysteine transporter 3 than in responders. Better cognition was associated with higher D-serine and lower glutamate-cysteine transporter 3 levels only in responders; this association was disrupted in the treatment resistant group. Treatment resistant patients and limited responders displayed early cognitive and persistent functioning impairment. The dysregulation of NMDAR co-agonist pathways provides underlying molecular mechanisms for cognitive deficits in treatment-resistant first-episode psychosis. If replicated, our findings would open ways to mechanistic biomarkers guiding response-based patient stratification and targeting cognitive improvement in clinical trials.
Druh dokumentu: Article
Other literature type
Popis súboru: application/pdf
Jazyk: English
ISSN: 1476-5578
1359-4184
DOI: 10.1038/s41380-024-02631-4
DOI: 10.48350/197694
Prístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/38849515
https://archive-ouverte.unige.ch/unige:184121
https://doi.org/10.1038/s41380-024-02631-4
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_23EAC9CDB4DD2
https://serval.unil.ch/notice/serval:BIB_23EAC9CDB4DD
https://serval.unil.ch/resource/serval:BIB_23EAC9CDB4DD.P001/REF.pdf
https://boris.unibe.ch/197694/
Rights: CC BY
Prístupové číslo: edsair.doi.dedup.....2b060d9c00dca680e4c35cf5b22e073c
Databáza: OpenAIRE
FullText Text:
  Availability: 0
CustomLinks:
  – Url: https://explore.openaire.eu/search/publication?articleId=doi_dedup___%3A%3A2b060d9c00dca680e4c35cf5b22e073c
    Name: EDS - OpenAIRE (s4221598)
    Category: fullText
    Text: View record at OpenAIRE
  – Url: https://resolver.ebscohost.com/openurl?sid=EBSCO:edsair&genre=article&issn=14765578&ISBN=&volume=29&issue=&date=20240607&spage=3669&pages=3669-3679&title=Molecular Psychiatry&atitle=Neurocognition%20and%20NMDAR%20co-agonists%20pathways%20in%20individuals%20with%20treatment%20resistant%20first-episode%20psychosis%3A%20a%203-year%20follow-up%20longitudinal%20study&aulast=Camporesi%2C%20Sara&id=DOI:10.1038/s41380-024-02631-4
    Name: Full Text Finder
    Category: fullText
    Text: Full Text Finder
    Icon: https://imageserver.ebscohost.com/branding/images/FTF.gif
    MouseOverText: Full Text Finder
  – Url: https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=EBSCO&SrcAuth=EBSCO&DestApp=WOS&ServiceName=TransferToWoS&DestLinkType=GeneralSearchSummary&Func=Links&author=Camporesi%20S
    Name: ISI
    Category: fullText
    Text: Nájsť tento článok vo Web of Science
    Icon: https://imagesrvr.epnet.com/ls/20docs.gif
    MouseOverText: Nájsť tento článok vo Web of Science
Header DbId: edsair
DbLabel: OpenAIRE
An: edsair.doi.dedup.....2b060d9c00dca680e4c35cf5b22e073c
RelevancyScore: 974
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 974.314025878906
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study
– Name: Author
  Label: Authors
  Group: Au
  Data: &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Camporesi%2C+Sara%22&quot;&gt;Camporesi, Sara&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Xin%2C+Lijing%22&quot;&gt;Xin, Lijing&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Golay%2C+Philippe%22&quot;&gt;Golay, Philippe&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Eap%2C+Chin+Bin%22&quot;&gt;Eap, Chin Bin&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cleusix%2C+Martine%22&quot;&gt;Cleusix, Martine&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Cuenod%2C+Michel%22&quot;&gt;Cuenod, Michel&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Fournier%2C+Margot%22&quot;&gt;Fournier, Margot&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Hashimoto%2C+Kenji%22&quot;&gt;Hashimoto, Kenji&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Jenni%2C+Raoul%22&quot;&gt;Jenni, Raoul&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Ramain%2C+Julie%22&quot;&gt;Ramain, Julie&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Restellini%2C+Romeo%22&quot;&gt;Restellini, Romeo&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Solida%2C+Alessandra%22&quot;&gt;Solida, Alessandra&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Conus%2C+Philippe%22&quot;&gt;Conus, Philippe&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Do%2C+Kim+Q%22&quot;&gt;Do, Kim Q&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Khadimallah%2C+Ines%22&quot;&gt;Khadimallah, Ines&lt;/searchLink&gt;
– Name: TitleSource
  Label: Source
  Group: Src
  Data: Mol Psychiatry&lt;br /&gt;Molecular psychiatry, vol. 29, no. 11, pp. 3669-3679&lt;br /&gt;Camporesi, Sara; Xin, Lijing; Golay, Philippe; Eap, Chin Bin; Cleusix, Martine; Cuenod, Michel; Fournier, Margot; Hashimoto, Kenji; Jenni, Raoul; Ramain, Julie; Restellini, Romeo; Solida, Alessandra; Conus, Philippe; Do, Kim Q; Khadimallah, Ines (2024). Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study. (In Press). Molecular psychiatry Springer Nature 10.1038/s41380-024-02631-4 &lt;http://dx.doi.org/10.1038/s41380-024-02631-4&gt;&lt;br /&gt;Camporesi, Sara; Xin, Lijing; Golay, Philippe; Eap, Chin Bin; Cleusix, Martine; Cuenod, Michel; Fournier, Margot; Hashimoto, Kenji; Jenni, Raoul; Ramain, Julie; Restellini, Romeo; Solida, Alessandra; Conus, Philippe; Do, Kim Q; Khadimallah, Ines (2024). Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study. Molecular psychiatry, 29(11), pp. 3669-3679. Springer Nature 10.1038/s41380-024-02631-4 &lt;http://dx.doi.org/10.1038/s41380-024-02631-4&gt;
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Springer Science and Business Media LLC, 2024.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2024
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Male%22&quot;&gt;Male&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Adult%22&quot;&gt;Adult&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Adolescent%22&quot;&gt;Adolescent&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psychotic+Disorders+%2F+metabolism%22&quot;&gt;Psychotic Disorders / metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Glutamic+Acid%22&quot;&gt;Glutamic Acid&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22610+Medicine+%26+health%22&quot;&gt;610 Medicine &amp; health&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%2C+Treatment-Resistant+%2F+metabolism%22&quot;&gt;Schizophrenia, Treatment-Resistant / metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Glutamic+Acid+%2F+metabolism%22&quot;&gt;Glutamic Acid / metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Neuropsychological+Tests%22&quot;&gt;Neuropsychological Tests&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Humans%22&quot;&gt;Humans&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Female%22&quot;&gt;Female&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Longitudinal+Studies%22&quot;&gt;Longitudinal Studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psychotic+Disorders%2Fdrug+therapy%22&quot;&gt;Psychotic Disorders/drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psychotic+Disorders%2Fmetabolism%22&quot;&gt;Psychotic Disorders/metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Receptors%2C+N-Methyl-D-Aspartate%2Fmetabolism%22&quot;&gt;Receptors, N-Methyl-D-Aspartate/metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Young+Adult%22&quot;&gt;Young Adult&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Follow-Up+Studies%22&quot;&gt;Follow-Up Studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognitive+Dysfunction%2Fdrug+therapy%22&quot;&gt;Cognitive Dysfunction/drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognitive+Dysfunction%2Fmetabolism%22&quot;&gt;Cognitive Dysfunction/metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Antipsychotic+Agents%2Ftherapeutic+use%22&quot;&gt;Antipsychotic Agents/therapeutic use&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Antipsychotic+Agents%2Fpharmacology%22&quot;&gt;Antipsychotic Agents/pharmacology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Case-Control+Studies%22&quot;&gt;Case-Control Studies&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognition%2Fphysiology%22&quot;&gt;Cognition/physiology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognition%2Fdrug+effects%22&quot;&gt;Cognition/drug effects&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%2C+Treatment-Resistant%2Fdrug+therapy%22&quot;&gt;Schizophrenia, Treatment-Resistant/drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%2C+Treatment-Resistant%2Fmetabolism%22&quot;&gt;Schizophrenia, Treatment-Resistant/metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Glutamic+Acid%2Fmetabolism%22&quot;&gt;Glutamic Acid/metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%2Fdrug+therapy%22&quot;&gt;Schizophrenia/drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%2Fmetabolism%22&quot;&gt;Schizophrenia/metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Brain%2Fmetabolism%22&quot;&gt;Brain/metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Receptors%2C+N-Methyl-D-Aspartate%22&quot;&gt;Receptors, N-Methyl-D-Aspartate&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Receptors%2C+N-Methyl-D-Aspartate+%2F+metabolism%22&quot;&gt;Receptors, N-Methyl-D-Aspartate / metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Article%22&quot;&gt;Article&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognition%22&quot;&gt;Cognition&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psychotic+Disorders+%2F+drug+therapy%22&quot;&gt;Psychotic Disorders / drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognitive+Dysfunction%22&quot;&gt;Cognitive Dysfunction&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognition+%2F+physiology%22&quot;&gt;Cognition / physiology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognitive+Dysfunction+%2F+drug+therapy%22&quot;&gt;Cognitive Dysfunction / drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia+%2F+metabolism%22&quot;&gt;Schizophrenia / metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Antipsychotic+Agents+%2F+pharmacology%22&quot;&gt;Antipsychotic Agents / pharmacology&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%2C+Treatment-Resistant+%2F+drug+therapy%22&quot;&gt;Schizophrenia, Treatment-Resistant / drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia+%2F+drug+therapy%22&quot;&gt;Schizophrenia / drug therapy&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Brain%22&quot;&gt;Brain&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognitive+Dysfunction+%2F+metabolism%22&quot;&gt;Cognitive Dysfunction / metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Psychotic+Disorders%22&quot;&gt;Psychotic Disorders&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Cognition+%2F+drug+effects%22&quot;&gt;Cognition / drug effects&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22616%2E89%22&quot;&gt;616.89&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%22&quot;&gt;Schizophrenia&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Brain+%2F+metabolism%22&quot;&gt;Brain / metabolism&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Antipsychotic+Agents+%2F+therapeutic+use%22&quot;&gt;Antipsychotic Agents / therapeutic use&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Schizophrenia%2C+Treatment-Resistant%22&quot;&gt;Schizophrenia, Treatment-Resistant&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22Antipsychotic+Agents%22&quot;&gt;Antipsychotic Agents&lt;/searchLink&gt;
– Name: Abstract
  Label: Description
  Group: Ab
  Data: This study aims to determine whether 1) individuals with treatment-resistant schizophrenia display early cognitive impairment compared to treatment-responders and healthy controls and 2) N-methyl-D-aspartate-receptor hypofunction is an underlying mechanism of cognitive deficits in treatment-resistance. In this case‒control 3-year-follow-up longitudinal study, n = 697 patients with first-episode psychosis, aged 18 to 35, were screened for Treatment Response and Resistance in Psychosis criteria through an algorithm that assigns patients to responder, limited-response or treatment-resistant category (respectively resistant to 0, 1 or 2 antipsychotics). Assessments at baseline: MATRICS Consensus Cognitive Battery; N-methyl-D-aspartate-receptor co-agonists biomarkers in brain by MRS (prefrontal glutamate levels) and plasma (D-serine and glutamate pathways key markers). Patients were compared to age- and sex-matched healthy controls (n = 114). Results: patient mean age 23, 27% female. Treatment-resistant (n = 51) showed lower scores than responders (n = 183) in processing speed, attention/vigilance, working memory, verbal learning and visual learning. Limited responders (n = 59) displayed an intermediary phenotype. Treatment-resistant and limited responders were merged in one group for the subsequent D-serine and glutamate pathway analyses. This group showed D-serine pathway dysregulation, with lower levels of the enzymes serine racemase and serine-hydroxymethyltransferase 1, and higher levels of the glutamate-cysteine transporter 3 than in responders. Better cognition was associated with higher D-serine and lower glutamate-cysteine transporter 3 levels only in responders; this association was disrupted in the treatment resistant group. Treatment resistant patients and limited responders displayed early cognitive and persistent functioning impairment. The dysregulation of NMDAR co-agonist pathways provides underlying molecular mechanisms for cognitive deficits in treatment-resistant first-episode psychosis. If replicated, our findings would open ways to mechanistic biomarkers guiding response-based patient stratification and targeting cognitive improvement in clinical trials.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: Article&lt;br /&gt;Other literature type
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: application/pdf
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 1476-5578&lt;br /&gt;1359-4184
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1038/s41380-024-02631-4
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.48350/197694
– Name: URL
  Label: Access URL
  Group: URL
  Data: &lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://pubmed.ncbi.nlm.nih.gov/38849515&quot; linkWindow=&quot;_blank&quot;&gt;https://pubmed.ncbi.nlm.nih.gov/38849515&lt;/link&gt;&lt;br /&gt;&lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://archive-ouverte.unige.ch/unige:184121&quot; linkWindow=&quot;_blank&quot;&gt;https://archive-ouverte.unige.ch/unige:184121&lt;/link&gt;&lt;br /&gt;&lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://doi.org/10.1038/s41380-024-02631-4&quot; linkWindow=&quot;_blank&quot;&gt;https://doi.org/10.1038/s41380-024-02631-4&lt;/link&gt;&lt;br /&gt;&lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_23EAC9CDB4DD2&quot; linkWindow=&quot;_blank&quot;&gt;http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_23EAC9CDB4DD2&lt;/link&gt;&lt;br /&gt;&lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://serval.unil.ch/notice/serval:BIB_23EAC9CDB4DD&quot; linkWindow=&quot;_blank&quot;&gt;https://serval.unil.ch/notice/serval:BIB_23EAC9CDB4DD&lt;/link&gt;&lt;br /&gt;&lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://serval.unil.ch/resource/serval:BIB_23EAC9CDB4DD.P001/REF.pdf&quot; linkWindow=&quot;_blank&quot;&gt;https://serval.unil.ch/resource/serval:BIB_23EAC9CDB4DD.P001/REF.pdf&lt;/link&gt;&lt;br /&gt;&lt;link linkTarget=&quot;URL&quot; linkTerm=&quot;https://boris.unibe.ch/197694/&quot; linkWindow=&quot;_blank&quot;&gt;https://boris.unibe.ch/197694/&lt;/link&gt;
– Name: Copyright
  Label: Rights
  Group: Cpyrght
  Data: CC BY
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsair.doi.dedup.....2b060d9c00dca680e4c35cf5b22e073c
PLink https://erproxy.cvtisr.sk/sfx/access?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=edsair&AN=edsair.doi.dedup.....2b060d9c00dca680e4c35cf5b22e073c
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41380-024-02631-4
    Languages:
      – Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 11
        StartPage: 3669
    Subjects:
      – SubjectFull: Male
        Type: general
      – SubjectFull: Adult
        Type: general
      – SubjectFull: Adolescent
        Type: general
      – SubjectFull: Psychotic Disorders / metabolism
        Type: general
      – SubjectFull: Glutamic Acid
        Type: general
      – SubjectFull: 610 Medicine & health
        Type: general
      – SubjectFull: Schizophrenia, Treatment-Resistant / metabolism
        Type: general
      – SubjectFull: Glutamic Acid / metabolism
        Type: general
      – SubjectFull: Neuropsychological Tests
        Type: general
      – SubjectFull: Humans
        Type: general
      – SubjectFull: Female
        Type: general
      – SubjectFull: Longitudinal Studies
        Type: general
      – SubjectFull: Psychotic Disorders/drug therapy
        Type: general
      – SubjectFull: Psychotic Disorders/metabolism
        Type: general
      – SubjectFull: Receptors, N-Methyl-D-Aspartate/metabolism
        Type: general
      – SubjectFull: Young Adult
        Type: general
      – SubjectFull: Follow-Up Studies
        Type: general
      – SubjectFull: Cognitive Dysfunction/drug therapy
        Type: general
      – SubjectFull: Cognitive Dysfunction/metabolism
        Type: general
      – SubjectFull: Antipsychotic Agents/therapeutic use
        Type: general
      – SubjectFull: Antipsychotic Agents/pharmacology
        Type: general
      – SubjectFull: Case-Control Studies
        Type: general
      – SubjectFull: Cognition/physiology
        Type: general
      – SubjectFull: Cognition/drug effects
        Type: general
      – SubjectFull: Schizophrenia, Treatment-Resistant/drug therapy
        Type: general
      – SubjectFull: Schizophrenia, Treatment-Resistant/metabolism
        Type: general
      – SubjectFull: Glutamic Acid/metabolism
        Type: general
      – SubjectFull: Schizophrenia/drug therapy
        Type: general
      – SubjectFull: Schizophrenia/metabolism
        Type: general
      – SubjectFull: Brain/metabolism
        Type: general
      – SubjectFull: Receptors, N-Methyl-D-Aspartate
        Type: general
      – SubjectFull: Receptors, N-Methyl-D-Aspartate / metabolism
        Type: general
      – SubjectFull: Article
        Type: general
      – SubjectFull: Cognition
        Type: general
      – SubjectFull: Psychotic Disorders / drug therapy
        Type: general
      – SubjectFull: Cognitive Dysfunction
        Type: general
      – SubjectFull: Cognition / physiology
        Type: general
      – SubjectFull: Cognitive Dysfunction / drug therapy
        Type: general
      – SubjectFull: Schizophrenia / metabolism
        Type: general
      – SubjectFull: Antipsychotic Agents / pharmacology
        Type: general
      – SubjectFull: Schizophrenia, Treatment-Resistant / drug therapy
        Type: general
      – SubjectFull: Schizophrenia / drug therapy
        Type: general
      – SubjectFull: Brain
        Type: general
      – SubjectFull: Cognitive Dysfunction / metabolism
        Type: general
      – SubjectFull: Psychotic Disorders
        Type: general
      – SubjectFull: Cognition / drug effects
        Type: general
      – SubjectFull: 616.89
        Type: general
      – SubjectFull: Schizophrenia
        Type: general
      – SubjectFull: Brain / metabolism
        Type: general
      – SubjectFull: Antipsychotic Agents / therapeutic use
        Type: general
      – SubjectFull: Schizophrenia, Treatment-Resistant
        Type: general
      – SubjectFull: Antipsychotic Agents
        Type: general
    Titles:
      – TitleFull: Neurocognition and NMDAR co-agonists pathways in individuals with treatment resistant first-episode psychosis: a 3-year follow-up longitudinal study
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Camporesi, Sara
      – PersonEntity:
          Name:
            NameFull: Xin, Lijing
      – PersonEntity:
          Name:
            NameFull: Golay, Philippe
      – PersonEntity:
          Name:
            NameFull: Eap, Chin Bin
      – PersonEntity:
          Name:
            NameFull: Cleusix, Martine
      – PersonEntity:
          Name:
            NameFull: Cuenod, Michel
      – PersonEntity:
          Name:
            NameFull: Fournier, Margot
      – PersonEntity:
          Name:
            NameFull: Hashimoto, Kenji
      – PersonEntity:
          Name:
            NameFull: Jenni, Raoul
      – PersonEntity:
          Name:
            NameFull: Ramain, Julie
      – PersonEntity:
          Name:
            NameFull: Restellini, Romeo
      – PersonEntity:
          Name:
            NameFull: Solida, Alessandra
      – PersonEntity:
          Name:
            NameFull: Conus, Philippe
      – PersonEntity:
          Name:
            NameFull: Do, Kim Q
      – PersonEntity:
          Name:
            NameFull: Khadimallah, Ines
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 06
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 14765578
            – Type: issn-print
              Value: 13594184
            – Type: issn-locals
              Value: edsair
            – Type: issn-locals
              Value: edsairFT
          Numbering:
            – Type: volume
              Value: 29
          Titles:
            – TitleFull: Molecular Psychiatry
              Type: main
ResultId 1